Kenneth Bate Net Worth

The estimated Net Worth of Kenneth Bate is at least $3.56 Million dollars as of 1 April 2024. Mr. Bate owns over 32,489 units of Madrigal Pharmaceuticals Inc stock worth over $2,891,530 and over the last 14 years he sold MDGL stock worth over $0. In addition, he makes $670,000 as Independent Director at Madrigal Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Bate MDGL stock SEC Form 4 insiders trading

Kenneth has made over 1 trades of the Madrigal Pharmaceuticals Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he exercised 32,489 units of MDGL stock worth $2,411,334 on 1 April 2024.

The largest trade he's ever made was exercising 32,489 units of Madrigal Pharmaceuticals Inc stock on 1 April 2024 worth over $2,411,334. On average, Kenneth trades about 533 units every 0 days since 2010. As of 1 April 2024 he still owns at least 12,410 units of Madrigal Pharmaceuticals Inc stock.

You can see the complete history of Mr. Bate stock trades at the bottom of the page.

Kenneth Bate biography

Kenneth M. Bate serves as Independent Director of the Company. Previously, Mr. Bate was the President and Chief Executive Officer of Archemix Corp., a privately-held biopharmaceutical company, a position he held from April 2009 through December 2011. From 2006 to April 2009, he served in various positions at NitroMed, Inc., a publicly-held pharmaceutical company, most recently as President and Chief Executive Officer. From 2002 to 2005, Mr. Bate served as Head of Commercial Operations and Chief Financial Officer at Millennium Pharmaceuticals, Inc., a biopharmaceutical company. Prior to joining Millennium Pharmaceuticals, Mr. Bate co-founded JSB Partners, LLC, a banking and advisory services firm for biopharmaceutical and life sciences companies. From 1990 to 1996, Mr. Bate was employed with Biogen, Inc., a publicly-held biotechnology company, first as its Chief Financial Officer and then as head of the commercial organization responsible for launching its multiple sclerosis business. Mr. Bate currently serves as chairman of the board of directors of the following publicly-held biopharmaceutical companies: AVEO Pharmaceuticals, Inc., Genocea Biosciences, Inc. and Catabasis Pharmaceuticals, Inc. In addition, Mr. Bate currently serves on the board of directors of Epizyme, Inc., a publicly-held biopharmaceutical company. During the last five years, Mr. Bate also served as chairman of the board of directors of Cubist Pharmaceuticals, Inc. and as a director of BioMarin Pharmaceuticals, Inc. and Vanda Pharmaceuticals Inc., each a publicly-held biopharmaceutical company. Mr. Bate holds a B.A. in Chemistry from Williams College and an M.B.A. from The Wharton School of the University of Pennsylvania.

What is the salary of Kenneth Bate?

As the Independent Director of Madrigal Pharmaceuticals Inc, the total compensation of Kenneth Bate at Madrigal Pharmaceuticals Inc is $670,000. There are 10 executives at Madrigal Pharmaceuticals Inc getting paid more, with Paul Friedman having the highest compensation of $6,093,190.

How old is Kenneth Bate?

Kenneth Bate is 69, he's been the Independent Director of Madrigal Pharmaceuticals Inc since 2016. There are 4 older and 12 younger executives at Madrigal Pharmaceuticals Inc. The oldest executive at Madrigal Pharmaceuticals Inc is David Milligan, 79, who is the Independent Director.

What's Kenneth Bate's mailing address?

Kenneth's mailing address filed with the SEC is C/O MADRIGAL PHARMACEUTICALS, INC., 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA, 19428.

Insiders trading at Madrigal Pharmaceuticals Inc

Over the last 8 years, insiders at Madrigal Pharmaceuticals Inc have traded over $471,222,585 worth of Madrigal Pharmaceuticals Inc stock and bought 443,785 units worth $79,114,183 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Paul A Friedman, and Bros. Advisors Lp667, L.P.B.... On average, Madrigal Pharmaceuticals Inc executives and independent directors trade stock every 56 days with the average trade being worth of $20,602,093. The most recent stock trade was executed by William John Sibold on 9 September 2024, trading 6,363 units of MDGL stock currently worth $1,551,490.

What does Madrigal Pharmaceuticals Inc do?

madrigal pharmaceuticals inc. is a biotechnology company based out of calle laguna del marquesado nª 19, nave 16 edificio adriana 1ª planta, polígono industrial la resina (villaverde), madrid, community of madrid, spain.

Complete history of Mr. Bate stock trades at AVEO Pharmaceuticals Inc, Biomarin Pharmaceutical, Astria Therapeutics Inc, Epizyme Inc, Genocea Biosciences Inc, Madrigal Pharmaceuticals Inc, and Vanda Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc executives and stock owners

Madrigal Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Paul Friedman,
  Chairman of the Board, Chief Executive Officer
• Rebecca Taub,
  President of Research and Development, Chief Medical Officer, Director
• Brian Lynch,
  Senior Vice President, General Counsel
• Marc Schneebaum,
  Chief Financial Officer, Senior Vice President
• James Daly,
  Independent Director
• Dr. Paul A. Friedman M.D.,
  Chairman & CEO
• Dr. Rebecca A. Taub M.D.,
  Founder, Chief Medical Officer, Pres of R&D and Director
• Remy Sukhija,
  Sr. VP & Chief Commercial Officer
• Brian J. Lynch J.D.,
  Sr. VP & Gen. Counsel
• Brian J. Lynch,
  Sr. VP & Gen. Counsel
• Kenneth Bate,
  Independent Director
• Richard Levy,
  Independent Director
• Keith Gollust,
  Independent Director
• David Milligan,
  Independent Director
• Frederick Craves,
  Lead Independent Director
• Remy Sukhija,
  Senior Vice President, Chief Commercial Officer
• Edward Chiang,
  Sr. VP of Clinical & Technical Operations
• Dr. Stephen Dodge M.B.A., Pharm.D.,
  Sr. VP & Global Head of Medical Affairs
• Dr. Robert E. Waltermire Ph.D.,
  Chief Pharmaceutical Devel. Officer
• Thomas W. Hare,
  Sr. VP of Clinical Management
• Dr. Kianoush Motesharei Ph.d.,
  Sr. VP of Bus. & Corp. Devel.
• Alex G. Howarth,
  Chief Financial Officer
• Bros. Advisors Lp667, L.P.B...,
  
• Bros. Advisors Lp667, L.P.B...,
  
• Chen Schor,
  Former President and CEO
• Wendy E Rieder,
  Former SVP, Gen. Counsel
• City Capital Llc Bay,
  Director
• City Capital Llc Bay City C...,
  
• Alex G. Howarth,
  Chief Financial Officer
• Robert E. Waltermire,
  Senior VP, Chief Pharma Dev.
• Bros. Advisors Lp Baker,
  
• Shannon T Kelley,
  General Counsel
• William John Sibold,
  President and CEO
• Carole Huntsman,
  Chief Commercial Officer
• Fred B Craves,